Chromax Chromium Picolinate Patent Infringement Alleged By AMBI
This article was originally published in The Tan Sheet
Executive Summary
Nutrition 21 "will continue to seek legal remedies" against companies infringing on its Chromax chromium picolinate use patents, the AMBI subsidiary said May 9, while announcing the latest in a series of suits that began last August.
You may also be interested in...
AMBI
Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)
AMBI
Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)
AMBI
Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)